Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Michelle Boyer"'
Autor:
Arnon P. Kater, Barbara F. Eichhorst, Carolyn J. Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani‐Mulero, Michelle Boyer, John F. Seymour
Publikováno v:
HemaSphere, Vol 8, Iss 8, Pp n/a-n/a (2024)
Abstract Immune dysregulation is a hallmark of chronic lymphocytic leukemia (CLL). Anti‐CD20 antibodies (e.g., rituximab [R]) can be combined with venetoclax (Ven) to treat CLL. However, anti‐CD20 antibodies can increase hypogammaglobulinemia ris
Externí odkaz:
https://doaj.org/article/e7a1b35722c44499b7700a85cc48aca9
Autor:
Arnon Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Maria Thadani-Mulero, Marcus Lefebure, Yanwen Jiang, Rosemary Millen, Michelle Boyer, John F Seymour
Publikováno v:
HemaSphere, Vol 7, p e492813f (2023)
Externí odkaz:
https://doaj.org/article/40a72c8b5e324b6bb0a316c864da72a7
Autor:
Jeffrey P. Sharman, Juliana M. L. Biondo, Michelle Boyer, Kirsten Fischer, Michael Hallek, Dingfeng Jiang, Arnon P. Kater, Michele Porro Lurà, William G. Wierda
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 492-506 (2022)
Abstract We reviewed the literature (January 2010–June 2021) on the effectiveness of debulking strategies before venetoclax initiation in patients with chronic lymphocytic leukemia to reduce tumor burden, downgrade tumor lysis syndrome (TLS) risk,
Externí odkaz:
https://doaj.org/article/c433192b9d0e4a749e2f5783f5e3d713
Autor:
Sasanka Handunnetti, Mary Ann Anderson, Andrew W. Roberts, Matthew S. Davids, Shuo Ma, Michelle Boyer, Jennifer Arzt, Abdullah Al Masud, Relja Popovic, Amanda Jacobson, Su Y. Kim, John F. Seymour
Publikováno v:
eJHaem, Vol 2, Iss 2, Pp 266-271 (2021)
Abstract Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients
Externí odkaz:
https://doaj.org/article/9c4a0e2139814ca2bc1507daf287db64
Autor:
Anthony R. Mato, Jeff P. Sharman, Juliana M.L. Biondo, Mei Wu, Yong Mun, Su Y. Kim, Kathryn Humphrey, Michelle Boyer, Qian Zhu, John F. Seymour
Publikováno v:
Haematologica, Vol 107, Iss 1 (2020)
Fixed-duration venetoclax plus rituximab (VenR) has a manageable safety profile and improves survival in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). We present data from the phase III MURANO study on the impact of vene
Externí odkaz:
https://doaj.org/article/14983132725448b99a159a67f7907e2a
Autor:
John F. Seymour, Su Y. Kim, Margaret Mantas, Jennifer A. Arzt, John C. Pesko, Ahmed Hamed Salem, Michelle Boyer, Thomas J. Kipps, Abhijeet Kumar, William G. Wierda, Vaishalee P. Kenkre, Andrew W. Roberts, Matthew S. Davids
Supplementary Data from Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d930d44959192426629f18934e4367
https://doi.org/10.1158/1078-0432.22481808
https://doi.org/10.1158/1078-0432.22481808
Autor:
John F. Seymour, Su Y. Kim, Margaret Mantas, Jennifer A. Arzt, John C. Pesko, Ahmed Hamed Salem, Michelle Boyer, Thomas J. Kipps, Abhijeet Kumar, William G. Wierda, Vaishalee P. Kenkre, Andrew W. Roberts, Matthew S. Davids
Purpose:We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non–Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c084b266890b431d48cad15c586dc0
https://doi.org/10.1158/1078-0432.c.6530778.v1
https://doi.org/10.1158/1078-0432.c.6530778.v1
Autor:
Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A Dobber, Clemens Mellink, Anne-Marie F van der Kevie-Kersemaekers, Ludo M Evers, Fransien de Boer, Harry R Koene, John Schreurs, Marjolein van der Klift, Gerjo A Velders, Ellen van der Spek, Hanneke M van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F M Posthuma, Hein P J Visser, Ilse Houtenbos, Cecile A M Idink, Djamila E Issa, Ellen C Dompeling, Henk C T van Zaanen, Hendrik Veelken, Henriette Levenga, Lidwine W Tick, Wim E Terpstra, Sanne H Tonino, Michelle Boyer, Mehrdad Mobasher, Mark-David Levin, Arnon P Kater
Publikováno v:
The Lancet Haematology, 9(3), e190-e199. Lancet Publishing Group
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
Background Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after f
Autor:
John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D’Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater
Publikováno v:
Seymour, J F, Kipps, T J, Eichhorst, B F, D'Rozario, J, Owen, C J, Assouline, S, Lamanna, N, Robak, T, de la Serna, J, Jaeger, U, Cartron, G, Montillo, M, Mellink, C, Chyla, B, Panchal, A, Lu, T, Wu, J Q, Jiang, Y, Lefebure, M, Boyer, M & Kater, A P 2022, ' Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab ', Blood, vol. 140, no. 8, pp. 839-850 . https://doi.org/10.1182/blood.2021015014
Blood, 140(8), 839-850. American Society of Hematology
Blood, 140(8), 839-850. American Society of Hematology
The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83c7132b29981ecd44d57ac24adc9bd1
https://research.vumc.nl/en/publications/44bbc898-4d41-4197-810b-c7285b14f884
https://research.vumc.nl/en/publications/44bbc898-4d41-4197-810b-c7285b14f884
Autor:
Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato
Publikováno v:
Blood, 6(15), 4553-4557. American Society of Hematology
Blood advances, 6(15), 4553-4557. American Society of Hematology
Thompson, M C, Harrup, R A, Coombs, C C, Roeker, L E, Pu, J J, Choi, M Y, Barr, P M, Allan, J N, Simkovi, M, Leslie, L, Rhodes, J, Chong, E A, Kamdar, M, Skarbnik, A, Lansigan, F, McCall, B, Saja, K, Dyer, M J S, Walter, H S, Lefebure, M, Thadani-Mulero, M, Boyer, M, Biondo, J, Sail, K, Manzoor, B S, Furman, R, Bantilan, K S, Goy, A, Feldman, T, Labella, D, Schuster, S J, Park, J, Palomba, L, Zelenetz, A, Eyre, T A, Kater, A P, Seymour, J F & Mato, A R 2022, ' Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen ', Blood, vol. 6, no. 15, pp. 4553-4557 . https://doi.org/10.1182/bloodadvances.2022007812
Blood advances, 6(15), 4553-4557. American Society of Hematology
Thompson, M C, Harrup, R A, Coombs, C C, Roeker, L E, Pu, J J, Choi, M Y, Barr, P M, Allan, J N, Simkovi, M, Leslie, L, Rhodes, J, Chong, E A, Kamdar, M, Skarbnik, A, Lansigan, F, McCall, B, Saja, K, Dyer, M J S, Walter, H S, Lefebure, M, Thadani-Mulero, M, Boyer, M, Biondo, J, Sail, K, Manzoor, B S, Furman, R, Bantilan, K S, Goy, A, Feldman, T, Labella, D, Schuster, S J, Park, J, Palomba, L, Zelenetz, A, Eyre, T A, Kater, A P, Seymour, J F & Mato, A R 2022, ' Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen ', Blood, vol. 6, no. 15, pp. 4553-4557 . https://doi.org/10.1182/bloodadvances.2022007812
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5788d2dcc76be1604266c786b4beeb47
https://research.vumc.nl/en/publications/dcf1cfe8-7b8c-4df5-b481-6746476ba1c1
https://research.vumc.nl/en/publications/dcf1cfe8-7b8c-4df5-b481-6746476ba1c1